# ACS and STEMI treatment: gender-related issues

Alaide Chieffo<sup>1\*</sup>, MD; Gill Louise Buchanan<sup>1</sup>, MBChB; Fina Mauri<sup>2</sup>, MD; Julinda Mehilli<sup>3</sup>, MD; Beatriz Vaquerizo<sup>4</sup>, MD; Anouska Moynagh<sup>5</sup>, MD; Roxana Mehran<sup>6</sup>, MD; Marie-Claude Morice<sup>5</sup>, MD; on behalf of the Women in Innovations group

San Raffaele Scientific Institute, Milan, Italy;
Hospital Universitari Germans Trias i Pujol, Badalona, Spain;
Deutsches Herzzentrum, Munich, Germany;
Sant Pau Hospital, Barcelona, Spain;
Institut Hospitalier Jacques Cartier, Massy, France;
Mount Sinai Medical Center, New York, NY, USA

# Abstract

Cardiovascular disease is the leading cause of death amongst women, with acute coronary syndromes (ACS) representing a significant proportion. It has been reported that in women presenting with ACS there is underdiagnosis and consequent undertreatment leading to an increase in hospital and long-term mortality.

Several factors have to be taken into account, including lack of awareness both at patient and at physician level. Women are generally not aware of the cardiovascular risk and symptoms, often atypical, and therefore wait longer to seek medical attention. In addition, physicians often underestimate the risk of ACS in women leading to a further delay in accurate diagnosis and timely appropriate treatment, including cardiac catheterisation and primary percutaneous coronary intervention, with consequent delayed revascularisation times.

It has been acknowledged by the European Society of Cardiology that gender disparities do exist, with a Class I, Level of Evidence B recommendation that both genders should be treated in the same way when presenting with ACS. However, there is still a lack of awareness and the mission of Women in Innovation, in association with Stent for Life, is to change the perception of women with ACS and to achieve prompt diagnosis and treatment.

# Introduction

Cardiovascular disease remains the leading cause of death amongst women<sup>1</sup>. The proportion of women with coronary artery disease (CAD) has risen markedly as life expectancy has increased, with a 32% estimated lifetime risk in women over the age of 40 years<sup>2</sup>.

Acute coronary syndromes (ACS), encompassing unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI), represent a large portion of the clinical presentation of CAD. Prompt revascularisation is essential to reduce ischaemic complications in patients with STEMI and high-risk ACS<sup>3</sup>. Despite the high proportion of women developing ACS, this condition appears to be underdiagnosed and undertreated, with suboptimal use of revascularisation and medical therapy. There are a number of reasons for this, including a lack of awareness of the problem by the women themselves. Additionally, women may present with atypical symptoms leading to a delay in diagnosis, with a common misconception amongst healthcare providers of worse outcomes leading to less invasive management strategies in women. This article aims to review the issues surrounding gender disparities in the identification and treatment of ACS.

\*Corresponding author: Interventional Cardiology Unit, San Raffaele Scientific Institute, Via Olgettina 60, IT-20132 Milan, Italy. E-mail: chieffo.alaide@hsr.it

### Gender differences in risk profiles

Women are typically older at presentation with ACS and have more comorbidities than their male counterparts<sup>4-16</sup>. It has been demonstrated that women presenting with ACS have a significantly higher prevalence of diabetes mellitus, hypertension, peripheral vascular disease and cerebrovascular disease<sup>17</sup>. Conversely, women are less likely to be smokers or have suffered previous myocardial infarction (MI) or revascularisation. The reasons for these differences are multifactorial and may be a consequence of the development of CAD at a later age in women. This can be attributed to differences in endogenous sex hormone production, particularly oestrogen, which has a protective effect until the menopause<sup>3,18</sup>.

In addition, it has to be taken into account that women presenting with ACS more frequently have coronary arteries without significant lesions observed at coronary angiography<sup>19-22</sup>. In fact, more often women have microvascular dysfunction<sup>23</sup>, different plaque morphology<sup>24,25</sup> and more common endothelial erosion<sup>21,22</sup>. Furthermore, in women presenting with ACS, different pathologies, such as spontaneous coronary artery dissection, are more frequent **(Figure 1)**.

# Gender differences in clinical presentation and diagnosis

Women may have atypical symptoms with the onset of ACS, including back or neck pain, pleuritic chest pain, indigestion and dyspnoea<sup>17,26-32</sup>. Alternative symptoms are not widely known to the general public and therefore not promptly recognised<sup>33</sup>. This leads to the first delay in the diagnosis of ACS. Indeed, it has been reported recently that women were more likely than men to present without chest pain (respectively 42.0% vs. 30.7%; p<0.001)<sup>34</sup>.


Following presentation to healthcare providers, ACS may not be suspected initially, due to an unclear history and general underestimation of CAD risk in women. Therefore, there is a delay in ECG acquisition, recognition of the problem and timely management. This results in the second delay in the diagnosis of ACS.

Notably, it has been reported that women more often present with UA/NSTEMI within the ACS spectrum compared with men<sup>17</sup> and this could explain the generally less "invasive" management. However, mortality after NSTEMI at longer-term follow-up is actually higher<sup>35</sup>. An online survey study to assess adherence to national cardiovascular guidelines, which included 100 cardiologists, demonstrated that despite a similar calculated risk women were assigned to a lower risk category for CAD than men<sup>36</sup>. Moreover, it has been reported that the most commonly cited rationale for undertaking a conservative approach in women was the perception by healthcare providers that they were at lower risk<sup>37</sup>.

However, despite the misconception of lower risk, it has been demonstrated that females with ACS actually present with more signs of heart failure than their male counterparts<sup>5</sup>. In these patients, there may actually be more to gain from early invasive treatment and revascularisation, which women may otherwise be denied.

# Gender differences in ACS management MEDICAL THERAPY

It has been shown that, when women present with a suspected ACS, they are less likely to receive aspirin (odds ratio [OR] 1.16; 95% confidence interval [CI] 1.13-1.20; p<0.01) or glycoprotein IIb/IIIa inhibitors (OR 1.10; 95% CI 1.08-1.13; p<0.01)<sup>17</sup>. A similar reduction in proven therapies was demonstrated at follow-up, with less optimal medical therapy prescribed, including beta-blockers and lipid-lowering agents<sup>4-6,9,17,29,38-40</sup>. Underutilisation of optimal evidence-based therapies can be associated with multiple factors, including age, the consequences of disease and the physician's decision to catheterise<sup>41</sup>.



**Figure 1.** An example of a less common presentation of acute coronary syndrome in a woman. This 45-year-old woman presented late to the emergency room and was subsequently delayed in diagnosis due to a lack of suspicion. Panel A demonstrates acute occlusion of the left main coronary artery (see arrow) secondary to spontaneous coronary artery dissection. Panel B demonstrates the extension of the dissection into the left anterior descending coronary artery (see arrow). Panel C shows the final result following percutaneous coronary intervention with implantation of a  $3.0 \times 28$  mm drug-eluting stent to seal the entry point of the dissection.

#### **REVASCULARISATION IN STEMI**


The benefit of early reperfusion in STEMI in both genders is now unquestionable and is reflected in current practice guidelines<sup>42</sup>. Despite this, even in patients presenting with STEMI, women have been shown to be less likely to be admitted to a hospital with the ability to perform percutaneous coronary intervention (PCI)<sup>43</sup>. In a recent study from Poland of 26,035 patients (34.5% were female), fewer women with STEMI underwent primary PCI earlier than 12 hours from symptom onset (35.8% vs. 44.0%; p<0.0001)<sup>9</sup>. Indeed, there was not only a significant difference in the onset to balloon time (255 [IQR 175-375] minutes vs. 241 [IQR 165-360] minutes; p<0.0001) but also in the door to balloon time (45 [IQR 30-70] minutes vs. 44 [IOR 30-68] minutes; p=0.032). This confirms delays not only in patient presentation, but also in the identification and management decision by the medical profession as described above. Examples of delay in diagnosis and treatment of STEMI in women are illustrated in Figure 2.

A large registry of 74,389 patients (30.0% women) again demonstrated a lower rate of PCI with stent in women (14.2% vs. 24.4%; p<0.001) with a subsequent higher rate of in-hospital mortality in women (respectively 14.8% vs. 6.1%; p<0.0001)<sup>39</sup>. Furthermore, a large study of 1,143,513 patients (42.1% women) showed that younger women (<45 years) presenting without chest pain had a higher mortality than men of the same age group (OR 1.18; 95% CI 1.00-1.39)<sup>34</sup>. However, a recent study has shown that despite female gender being a predictor of early death, it does not appear to be a predictor at 12 months (OR 1.02; 95% CI 0.96-1.09; p=NS)<sup>9</sup>.

#### **REVASCULARISATION IN NSTEMI**

Numerous studies have demonstrated that in this high-risk population women are offered cardiac catheterisation and PCI less frequently than men **(Table 1)**. Regarding the management of NSTEMI, the advantage of an early invasive strategy in women has been less clear than in males, with prior interventional studies, including the "Fragmin and Fast Revascularization during In Stability in Coronary artery disease" (FRISC) II and the "Randomised Intervention Trial of unstable Angina" (RITA) 3 trials, demonstrating a clear benefit with a routine early invasive strategy in men, but not in women<sup>20,44</sup>. However, interestingly in the FRISC II trial, the higher event rate in females treated with an early invasive strategy seemed largely due to an increased rate of death and MI in the women undergoing CABG<sup>20</sup>.

Conversely, the "Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction-18" (TACTICS-TIMI 18) trial showed a similar benefit of an early invasive strategy between genders in those with



**Figure 2.** Examples of delayed diagnoses and treatment of women with STEMI. The upper panels A, B and C show evidence of an acute thrombotic occlusion of the right coronary artery on coronary angiography of a 58-year-old female Caucasian patient. She presented with a 14-hour history of chest pain, treated with direct  $3.0 \times 16$  mm bare metal stent implantation, with a good final angiographic result. Panels D, E and F show a subacute right coronary artery occlusion (two-day history of intermittent chest pain) of a 37-year-old Sri Lankan, treated with two  $(3.0 \times 28 \text{ mm and } 3.0 \times 13 \text{ mm})$  bare metal stents and good final result.

Study	Year	Number of patients	% Women in study	% Women undergoing angiography	% Men undergoing angiography	Significance
Mahon et al <sup>68</sup>	2000	1,059	40.0	24.1	38.0	p<0.001
Anand et al <sup>4</sup>	2005	12,562	38.5	39.4	45.5	p=0.0001
Blomkalns et al⁵	2005	35,875	40.6	60.1	71.1	OR 0.70
Heer et al <sup>65</sup>	2006	6,358	34.1	60.7	76.9	p<0.001
Alfredsson et al <sup>66</sup>	2007	53,781	36.7	29.0	37.0	OR 1.44
Jneid et al <sup>47</sup>	2008	78,254	39.2	45.6	56.2	p<0.0001
Hvelplund et al <sup>19</sup>	2010	18,262	32.0	32.0	68.0	OR 0.68
Bugiardini et al <sup>41</sup>	2011	6,558	31.8	41.8	49.6	p<0.0001
Poon et al (ACS I) <sup>37</sup>	2012	3,295	33.6	34.6	41.9	p<0.001
Poon et al (ACS II) <sup>37</sup>	2012	1,956	32.9	57.6	68.4	p<0.001

elevated biomarkers<sup>22</sup>. A further sex specific analysis showed a comparable benefit in both men and women if they were creatine kinase or troponin positive. However, those women with negative enzymes had higher event rates with an early invasive strategy<sup>45</sup>.

More recently, a gender substudy of the "Organization for the Assessment of Strategies for Ischemic Syndromes" (OASIS) 5 trial showed no differences between routine invasive or selective invasive (coronary angiography only if symptoms or signs of severe ischaemia) strategies in the primary outcome of death, MI or stroke; however, of note, there was a higher rate of death with a routine invasive strategy<sup>46</sup>. This was suggested to be due to the fact that women have less obstructive coronary stenoses, thereby diluting the treatment benefit in addition to more risk associated with CABG as suggested in the FRISC II trial. However, even after adjustment for the extent of disease, age and comorbidities, women with ACS have still been shown to be less likely to be revascularised<sup>19</sup>.

A number of studies have demonstrated increased in-hospital mortality amongst women following ACS (**Table 2**). A large US "Get With The Guidelines Coronary Artery Disease Database" of

78,254 patients with both STEMI and NSTEMI, of which 39.0% were female, demonstrated an unadjusted mortality of 8.2% in women compared to 5.7% in men (p<0.0001). Following multivariable adjustment, despite the fact that these differences were no longer observed in the overall cohort (adjusted OR 1.04; 95% CI 0.99-1.10), in the STEMI group there remained a higher mortality in women (respectively 10.2% vs. 5.5%; p<0.0001)<sup>47</sup>. A contemporary study of 14,196 NSTEMI patients in Canada showed women had a higher in-hospital mortality (adjusted OR 1.26; 95% CI 1.02-1.56; p=0.036), irrespective of age (p for interaction 0.76)<sup>37</sup>.

Conversely, in the "Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines" (CRUSADE) registry, no difference according to adjusted in-hospital mortality between women and men was observed (respectively 5.6% vs. 4.3%; adjusted OR 1.01; 95% CI 0.90-1.13)<sup>5</sup>.

The lack of gender-related difference in mortality has frequently been reported in registry studies in which women and men with acute MI underwent primary PCI<sup>17,48,49</sup>. The American College of

Study	Year	Number of patients	% Women	Female mortality	Male mortality	Significance			
Blomkalns et al⁵	2005	35,875	41.0	5.6	4.3	OR 1.27			
Elkoustaf et al64	2006	1,197	31.8	0.3	1.1	p=0.137			
Heer et al <sup>65</sup>	2006	16,817	34.1	6.8	4.1	p<0.001			
Alfredsson et al66	2007	53,781	37.0	7.0	5.0	p=NS			
Radovanovic et al <sup>67</sup>	2007	20,290	28.0	10.7	6.3	p<0.001			
Jneid et al47	2008	78,254	39.0	8.2	5.7	p<0.0001			
Akhter et al <sup>17</sup>	2009	199,690	34.1	2.2	1.4	p=0.52			
Al-Fiadh et al <sup>51</sup>	2011	2,952	27.2	3.9	2.0	p<0.001			
Bugiardini et al <sup>41</sup>	2011	6,558	31.8	3.4	2.2	p=0.0078			
Poon et al <sup>37</sup>	2012	14,196	34.3	2.7	1.6	p<0.001			
OR: odds ratio; NS: not significant.									

Cardiology National Cardiovascular Data Registry of 199,690 patients (34.0% women) showed an adjusted in-hospital mortality similar amongst genders (women 2.2% vs. men 1.4%; p=0.52)<sup>17</sup>.

A mortality difference in patients less frequently treated with PCI has also been demonstrated at more long-term follow-up. The Canadian Acute Coronary Syndrome registry demonstrated a significant difference in mortality at 12 months between genders (women 10.47% vs. men 8.02%;  $p=0.0017)^{41}$ . However, in the majority of registry studies in which the proportion of revascularised patients is high, no differences in long-term mortality have been reported<sup>48,50-52</sup>. Interestingly, women who underwent primary PCI within the first 48 hours after symptom onset did benefit more than their male counterparts (age-adjusted mortality risk at one year after revascularisation 0.65; 95% CI 0.49-0.87;  $p=0.004)^{48}$ . A higher degree of myocardial salvage after reperfusion in women compared to men might be a possible explanation for these findings<sup>49</sup>.

Recently, although the Task Force for the management of ACS in patients presenting without persistent ST-segment elevation of the European Society of Cardiology acknowledged that gender disparities do exist, they nevertheless recommended a Class I, Level of Evidence B indication that both genders should be treated in the same way when presenting with ACS<sup>53</sup>.

**Figure 3** demonstrates a thrombotic sub-occlusive left anterior descending coronary artery lesion in a 53-year-old woman presenting with NSTEMI. It is imperative that each individual should follow careful risk stratification for ischaemic and bleeding risks, incorporating clinical evaluation, biomarkers, comorbidities and risk scores.

#### **BLEEDING AND VASCULAR COMPLICATIONS**


Higher rates of procedural complications, in particular vascular complications and bleeding, can be increased as much as fourfold in the female population<sup>3,9,17,54</sup>. Female sex has been shown to be an independent predictor of bleeding in several ACS trials with different anticoagulation strategies<sup>50,55-57</sup>. Furthermore, the "Global Registry

of Acute Coronary Events" (GRACE) registry demonstrated the adjusted OR for bleeding was 1.71 (95% CI 1.35-2.17) in women compared with men<sup>58</sup>. Nevertheless, the use of glycoprotein IIb/IIIa inhibitors has not been reported as an independent risk for major vascular complications in women<sup>3,59,60</sup>.

In recent years much focus has been placed on reducing bleeding in patients requiring urgent intervention, with bivalirudin emerging as a possible alternative in STEMI patients<sup>61</sup>. Furthermore, in a gender sub-analysis of the "Randomised comparison of Bivalirudin versus Heparin in patients undergoing early invasive management for acute coronary syndrome without ST elevation" (ACUITY) study, comprising 13,819 patients (30.1% women), the use of bivalirudin monotherapy rather than heparin plus glycoprotein IIb/IIIa inhibitors reduced the rate of major bleeding at 30 days in the women undergoing PCI (12.0% vs. 6.0%; p<0.001) without an increase in ischaemia-driven outcomes. Furthermore, treatment with heparin rather than bivalirudin was an independent predictor of major bleeding (hazard ratio [HR] 1.7; 95% CI 1.3-2.22; p=0.0002)<sup>50</sup>.

## Under-representation of women in ACS trials

It is important to emphasise that historically women have been poorly represented in coronary clinical trials, typically comprising approximately 30% of the overall population. Several factors have to be taken into account, including inclusion criteria such as age, clinical presentation and timing of onset of symptoms. In addition, social factors should also be considered, such as less likelihood of women participating in clinical studies. The under-representation of women in clinical trials may clearly lead to an important bias in the interpretation of the results and subsequently to extending these to the female population. Clinical trials in the setting of ACS, with a larger representation of women and dedicated questions for gender-based issues, are warranted in order to understand better the pathophysiology of CAD and ACS in women and to ensure a tailored treatment of this patient population.



**Figure 3.** *NSTEMI in a 53-year-old woman, with a history of breast cancer treated with mastectomy, presenting with sudden onset chest pain. Despite no changes on electrocardiogram, echocardiography revealed some apical hypokinesia. The patient therefore underwent coronary angiography which demonstrated a subocclusive thrombotic lesion of the proximal left anterior descending coronary artery (Panel A arrowed), treated successfully with a 3.0 \times 16 mm bare metal stent (Panel B).* 

# Conclusions

Women with ACS tend to present later, face delays in diagnosis, undergo less invasive management and receive less effective medical management than their male counterparts. It is essential that as medical practitioners we aim to reduce these gender disparities in ACS management and ensure that women receive appropriate treatment from which they can benefit. The barriers that contribute to treatment disparities in women require further investigation. Women in Innovation, in association with Stent for Life, aim to develop greater awareness of this problem which may assist in bridging the gap between current guidelines and management practices<sup>62,63</sup>.

### **Conflict of interest statement**

R. Mehran receives research grants from Sanofi/BMS, TMC and DSI/Lilly and is a Consultant/Advisory Board for Regado Biosciences, AstraZeneca, Abbott Vascular and Janssen. The other authors have nothing to disclose in relation to this manuscript.

#### References

1. Stramba-Badiale M, Fox KM, Priori SG, Collins P, Daly C, Graham I, Jonsson B, Schenck-Gustafsson K, Tendera M. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. *Eur Heart J.* 2006;27: 994-1005.

2. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*. 2006;113:e85-151.

3. Lansky AJ, Hochman JS, Ward PA, Mintz GS, Fabunmi R, Berger PB, New G, Grines CL, Pietras CG, Kern MJ, Ferrell M, Leon MB, Mehran R, White C, Mieres JH, Moses JW, Stone GW, Jacobs AK. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: A statement for healthcare professionals from the American Heart Association. *Circulation*. 2005;111: 940-53.

4. Anand SS, Xie CC, Mehta S, Franzosi MG, Joyner C, Chrolavicius S, Fox KA, Yusuf S. Differences in the management and prognosis of women and men who suffer from acute coronary syndromes. *J Am Coll Cardiol.* 2005;46:1845-51.

5. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, Brogan GX Jr, Boden WE, Roe MT, Ohman EM, Gibler WB, Newby LK. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. *J Am Coll Cardiol.* 2005;45:832-7.

6. Vaccarino V, Rathore SS, Wenger NK, Frederick PD, Abramson JL, Barron HV, Manhapra A, Mallik S, Krumholz HM.

Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. *N Engl J Med.* 2005;353:671-82.

7. Mikhail GW. Coronary revascularisation in women. *Heart*. 2006;92:iii19-23.

8. Jacobs AK. Women, ischemic heart disease, revascularization, and the gender gap: What are we missing? *J Am Coll Cardiol*. 2006;47:S63-5.

9. Sadowski M, Gasior M, Gierlotka M, Janion M, Polonski L. Gender-related differences in mortality after ST-segment elevation myocardial infarction: a large multicentre national registry. *EuroIntervention*. 2011;6:1068-72.

10. Hochman JS, Tamis JE, Thompson TD, Weaver WD, White HD, Van de Werf F, Aylward P, Topol EJ, Califf RM. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. *N Engl J Med.* 1999;341:226-32.

11. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. *Lancet.* 2004;364:937-52.

12. Rosengren A, Wallentin L, A KG, Behar S, Battler A, Hasdai D. Sex, age, and clinical presentation of acute coronary syndromes. *Eur Heart J.* 2004;25:663-70.

13. Rosengren A, Wallentin L, Simoons M, Gitt AK, Behar S, Battler A, Hasdai D. Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey. *Eur Heart J.* 2006;27:789-95.

14. Simon T, Mary-Krause M, Cambou JP, Hanania G, Gueret P, Lablanche JM, Blanchard D, Genes N, Danchin N. Impact of age and gender on in-hospital and late mortality after acute myocardial infarction: Increased early risk in younger women: Results from the French nation-wide USIC registries. *Eur Heart J.* 2006;27:1282-88.

15. Shavelle DM, Rasouli ML, Frederick P, Gibson CM, French WJ; National Registry of Myocardial Infarction Investigators. Outcome in patients transferred for percutaneous coronary intervention (a national registry of myocardial infarction 2/3/4 analysis). *Am J Cardiol.* 2005;96:1227-32.

16. Perers E, Caidahl K, Herlitz J, Sjolin M, Karlson BW, Karlsson T, Hartford M. Spectrum of acute coronary syndromes: History and clinical presentation in relation to sex and age. *Cardiology*. 2004;102:67-76.

17. Akhter N, Milford-Beland S, Roe MT, Piana RN, Kao J, Shroff A. Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). *Am Heart J.* 2009;157:141-8.

18. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. *Circulation*. 1990;81:1680-7.

19. Hvelplund A, Galatius S, Madsen M, Rasmussen JN, Rasmussen S, Madsen JK, Sand NP, Tilsted HH, Thayssen P, Sindby E,

Hojbjerg S, Abildstrom SZ. Women with acute coronary syndrome are less invasively examined and subsequently less treated than men. *Eur Heart J.* 2010;31:684-90.

20. Lagerqvist B, Säfström K, Ståhle E, Wallentin L, Swahn E; FRISC II Study Group Investigators. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. *J Am Coll Cardiol.* 2001;38:41-8.

21. Clayton TC, Pocock SJ, Henderson RA, Poole-Wilson PA, Shaw TR, Knight R, Fox KA. Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial. *Eur Heart J.* 2004;25:1641-50.

22. Glaser R, Herrmann HC, Murphy SA, Demopoulos LA, DiBattiste PM, Cannon CP, Braunwald E. Benefit of an early invasive management strategy in women with acute coronary syndromes. *JAMA*. 2002;288:3124-9.

23. Wong TY, Klein R, Sharrett AR, Duncan BB, Couper DJ, Tielsch JM, Klein BE, Hubbard LD. Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The atherosclerosis risk in communities study. *JAMA*. 2002;287:1153-9.

24. Burke AP, Farb A, Malcom GT, Liang Y, Smialek J, Virmani R. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. *Circulation.* 1998;97:2110-6.

25. Burke AP, Virmani R, Galis Z, Haudenschild CC, Muller JE. 34th Bethesda Conference: Task force #2--What is the pathologic basis for new atherosclerosis imaging techniques? *J Am Coll Cardiol.* 2003;41:1874-86.

26. Dey S, Flather MD, Devlin G, Brieger D, Gurfinkel EP, Steg PG, Fitzgerald G, Jackson EA, Eagle KA; Global Registry of Acute Coronary Events investigators. Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. *Heart.* 2009;95:20-6.

27. Goldberg RJ, O'Donnell C, Yarzebski J, Bigelow C, Savageau J, Gore JM. Sex differences in symptom presentation associated with acute myocardial infarction: A population-based perspective. *Am Heart J.* 1998;136:189-95.

28. Thuresson M, Jarlov MB, Lindahl B, Svensson L, Zedigh C, Herlitz J. Symptoms and type of symptom onset in acute coronary syndrome in relation to ST elevation, sex, age, and a history of diabetes. *Am Heart J.* 2005;150:234-42.

29. Peterson ED, Shah BR, Parsons L, Pollack CV Jr, French WJ, Canto JG, Gibson CM, Rogers WJ. Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. *Am Heart J.* 2008;156:1045-55.

30. Canto JG, Goldberg RJ, Hand MM, Bonow RO, Sopko G, Pepine CJ, Long T. Symptom presentation of women with acute coronary syndromes: myth vs reality. *Arch Intern Med.* 2007;167:2405-13.

31. Mackay MH, Ratner PA, Johnson JL, Humphries KH, Buller CE. Gender differences in symptoms of myocardial ischaemia. *Eur Heart J.* 2011;32:3107-14.

32. Brieger D, Eagle KA, Goodman SG, Steg PG, Budaj A, White K, Montalescot G; GRACE Investigators. Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. *Chest.* 2004;126:461-9.

33. Lefler LL, Bondy KN. Women's delay in seeking treatment with myocardial infarction: A meta-synthesis. *J Cardiovasc Nurs*. 2004;19:251-68.

34. Canto JG. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. *JAMA*. 2012;307:813-22.

35. Terkelsen CJ, Lassen JF, Nørgaard BL, Gerdes JC, Jensen T, Gøtzsche LB, Nielsen TT, Andersen HR. Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort. *Eur Heart J.* 2005;26:18-26.

36. Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, Fabunmi RP, Kwan J, Mills T, Simpson SL. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. *Circulation*. 2005;111:499-510.

37. Poon S, Goodman SG, Yan RT, Bugiardini R, Bierman AS, Eagle KA, Johnston N, Huynh T, Grondin FR, Schenck-Gustafsson K, Yan AT. Bridging the gender gap: Insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes. *Am Heart J.* 2012;163: 66-73.

38. Daly C, Clemens F, Lopez Sendon JL, Tavazzi L, Boersma E, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W, Thygesen K, Verheugt F, Fox KM. Gender differences in the management and clinical outcome of stable angina. *Circulation*. 2006; 113:490-8.

39. Milcent C, Dormont B, Durand-Zaleski I, Steg PG. Gender differences in hospital mortality and use of percutaneous coronary intervention in acute myocardial infarction: microsimulation analysis of the 1999 nationwide French hospitals database. *Circulation*. 2007;115:833-9.

40. Mingo S, Goicolea J, Nombela L, Sufrate E, Blasco A, Millán I, Ocaranza R, Fernández-Díaz JA, Ortigosa J, Romero Y, Alonso-Pulpón L. Primary percutaneous angioplasty. An analysis of reperfusion delays, their determining factors and their prognostic implications. *Rev Esp Cardiol.* 2009;62:15-22.

41. Bugiardini R, Yan AT, Yan RT, Fitchett D, Langer A, Manfrini O, Goodman SG. Factors influencing underutilization of evidence-based therapies in women. *Eur Heart J.* 2011;32:1337-44.

42. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J.* 2008;29: 2909-45. 43. Fang J, Alderman MH. Gender differences of revascularization in patients with acute myocardial infarction. *Am J Cardiol.* 2006;97:1722-6.

44. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, Wheatley DJ, Pocock SJ. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. *Lancet.* 2002;360:743-51.

45. O'Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Wallentin L, Windhausen F, Sabatine MS. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. *JAMA*. 2008;300:71-80.

46. Swahn E, Alfredsson J, Afzal R, Budaj A, Chrolavicius S, Fox K, Jolly S, Mehta SR, de Winter R, Yusuf S. Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials. *Eur Heart J.* 2012;33:51-60.

47. Jneid H, Fonarow GC, Cannon CP, Hernandez AF, Palacios IF, Maree AO, Wells Q, Bozkurt B, Labresh KA, Liang L, Hong Y, Newby LK, Fletcher G, Peterson E, Wexler L. Sex differences in medical care and early death after acute myocardial infarction. *Circulation.* 2008;118:2803-10.

48. Mehilli J, Kastrati A, Dirschinger J, Pache J, Seyfarth M, Blasini R, Hall D, Neumann FJ, Schomig A. Sex-based analysis of outcome in patients with acute myocardial infarction treated predominantly with percutaneous coronary intervention. *JAMA*. 2002; 287:210-5.

49. Mehilli J, Ndrepepa G, Kastrati A, Nekolla SG, Markwardt C, Bollwein H, Pache J, Martinoff S, Dirschinger J, Schwaiger M, Schomig A. Gender and myocardial salvage after reperfusion treatment in acute myocardial infarction. *J Am Coll Cardiol.* 2005;45: 828-31.

50. Lansky AJ, Mehran R, Cristea E, Parise H, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Stone GW. Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). *Am J Cardiol.* 2009;103:1196-203.

51. Al-Fiadh AH, Andrianopoulos N, Farouque O, Yan BP, Duffy SJ, Charter K, Tongyoo S, New G, Yip T, Brennan A, Proimos G, Reid CM, Ajani AE, Clark DJ. Contemporary outcomes in women undergoing percutaneous coronary intervention for acute coronary syndromes. *Int J Cardiol.* 2011;151:195-9.

52. Alfredsson J, Lindback J, Wallentin L, Swahn E. Similar outcome with an invasive strategy in men and women with non-STelevation acute coronary syndromes: from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). *Eur Heart J.* 2011;32:3128-36.

53. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, Bax JJ, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S, Achenbach S, Badimon L, Bertrand M, Botker HE, Collet JP, Crea F, Danchin N, Falk E, Goudevenos J, Gulba D, Hambrecht R, Herrmann J, Kastrati A, Kjeldsen K, Kristensen SD, Lancellotti P, Mehilli J, Merkely B, Montalescot G, Neumann FJ, Neyses L, Perk J, Roffi M, Romeo F, Ruda M, Swahn E, Valgimigli M, Vrints CJ, Widimsky P. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999-3054.

54. Peterson ED, Lansky AJ, Kramer J, Anstrom K, Lanzilotta MJ. Effect of gender on the outcomes of contemporary percutaneous coronary intervention. *Am J Cardiol.* 2001;88: 359-64.

55. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, White HD, Moses JW, King SB 3rd, Ohman EM, Stone GW. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. *J Am Coll Cardiol.* 2007;49:1362-8.

56. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, Pollack C, Gibler WB, Ohman EM, Peterson ED. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. *JAMA*. 2005;294:3108-16.

57. Alexander KP, Chen AY, Newby LK, Schwartz JB, Redberg RF, Hochman JS, Roe MT, Gibler WB, Ohman EM, Peterson ED. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. *Circulation*. 2006;114:1380-7.

58. Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, White K, Goldberg RJ. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). *Eur Heart J.* 2003;24:1815-23.

59. Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, Kleiman NS, Tcheng JE, Califf R, Lincoff AM. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa block-ade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. *J Am Coll Cardiol.* 2000;36:381-6.

EuroIntervention 2012;8:P27-P35

60. Fernandes LS, Tcheng JE, O'Shea JC, Weiner B, Lorenz TJ, Pacchiana C, Berdan LG, Maresh KJ, Joseph D, Madan M, Mann T, Kilaru R, Hochman JS, Kleiman NS. Is glycoprotein IIb/ IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study. *J Am Coll Cardiol.* 2002;40:1085-91.

61. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. *Lancet*. 2009;374:1149-59.

62. Chieffo A, Hoye A, Mauri F, Mikhail GW, Ammerer M, Grines C, Grinfeld L, Madan M, Presbitero P, Skelding KA, Weiner BH, Mehran R. Gender-based issues in interventional cardiology: a consensus statement from the women in innovations (WIN) initiative. *EuroIntervention*. 2010;5:773-9.

63. Best PJ, Skelding KA, Mehran R, Chieffo A, Kunadian V, Madan M, Mikhail GW, Mauri F, Takahashi S, Honye J, Hernandez-Antolin R, Weiner BH. SCAI consensus document on occupational radiation exposure to the pregnant cardiologist and technical personnel. *EuroIntervention*. 2011;6:866-74.

64. Elkoustaf RA, Mamkin I, Mather JF, Murphy D, Hirst JA, Kiernan FJ, McKay RG. Comparison of results of percutaneous coronary intervention for non-ST-elevation acute myocardial infarction or unstable angina pectoris in men versus women. *Am J Cardiol.* 2006;98:182-6. 65. Heer T, Gitt AK, Juenger C, Schiele R, Wienbergen H, Towae F, Gottwitz M, Zahn R, Zeymer U, Senges J. Gender differences in acute non-ST-segment elevation myocardial infarction. *Am J Cardiol.* 2006;98:160-6.

66. Alfredsson J, Stenestrand U, Wallentin L, Swahn E. Gender differences in management and outcome in non-ST-elevation acute coronary syndrome. *Heart.* 2007;93:1357-62.

67. Radovanovic D, Erne P, Urban P, Bertel O, Rickli H, Gaspoz JM. Gender differences in management and outcomes in patients with acute coronary syndromes: results on 20,290 patients from the AMIS Plus Registry. *Heart.* 2007;93:1369-75.

68. Mahon NG, McKenna CJ, Codd MB, O'Rorke C, McCann HA, Sugrue DD. Gender differences in the management and outcome of acute myocardial infarction in unselected patients in the thrombolytic era. *Am J Cardiol.* 2000;85:921-6.